Ipilimumab

Most patients with renal cell carcinoma ineligible for surgery and ablation achieved tumor reduction after treatment with nivolumab plus ipilimumab, according to study results.

Cabozantinib combined with nivolumab and ipilimumab was "reasonably well tolerated," though it did not display an efficacy advantage over monotherapy, Bhavana Konda, MD, MPH, said in an interview with Healio.

An experimental test may help predict which patients with cancer may develop disease recurrence after immunotherapy treatment, according to study results published in Clinical Cancer Research.

The combination of nivolumab and ipilimumab after nephrectomy failed to extend DFS among patients with localized renal cell carcinoma at high risk for relapse, results of the phase 3 CheckMate 914 trial showed.

This year’s European Society for Medical Oncology Congress featured potentially practice-changing research in kidney cancer, cutaneous squamous cell carcinoma, lung cancer and melanoma.

Two cycles of neoadjuvant nivolumab plus low-dose ipilimumab induced durable pathologic responses among patients with mismatch repair-deficient colon cancer, according to study results presented at ESMO Congress.

Cabozantinib plus nivolumab and ipilimumab conferred a significant PFS benefit vs. nivolumab and ipilimumab alone among patients with advanced renal cell carcinoma, according to results of the COSMIC-313 trial presented at ESMO Congress.

Part A of a phase 3 trial assessing adjuvant nivolumab and ipilimumab for certain patients with renal cell carcinoma failed to meet the primary endpoint of DFS, according to topline data released by the agents’ manufacturer.

Jedd Wolchok, MD, PhD, FASCO, has been appointed director of Meyer Cancer Center at Weill Cornell Medicine.

CHICAGO — Among previously untreated patients with metastatic non-small cell lung cancer, nivolumab plus ipilimumab provided durable, long-term clinical benefit at 5-year follow-up compared with chemotherapy.